Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA): CAN10 programme acquired by Otsuka
Published by Arron Aatkar, PhD

Cantargia has announced that its CAN10 IL1RAP immunology programme has been acquired by Otsuka Pharmaceutical. Deal terms include an upfront payment of US$33m, plus up to US$580m in development, regulatory and commercial milestone payments. The company is also eligible for up to double digits tiered earn-out payments from global product sales. The deal is expected to close within Q325, after which, Otsuka will become responsible for the development and commercialisation of CAN10.

Latest

Healthcare | Comment

Herantis Pharma (HEL: HRTIS) – a step closer to Phase II

Investment Companies | Comment

The Biotech Growth Trust (BIOG) reported encouraging H126 results

TMT | Comment

Nanoco (LSE:NANO) settles LG litigation for $5m

Healthcare | Comment

Mendus (OMX: IMMU) announces c SEK50m directed share issue